京新药业(002020) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥808,255,395.68, representing a 1.64% increase year-over-year[5] - Net profit attributable to shareholders for the same period was ¥158,448,752.24, up 7.34% compared to the previous year[5] - The net profit excluding non-recurring gains and losses increased by 42.75% to ¥146,353,981.33 in Q3 2021[5] - Total operating revenue for the current period reached ¥2,468,167,432.84, a slight increase from ¥2,435,720,765.21 in the previous period, representing a growth of approximately 1.0%[28] - Net profit for the current period was ¥430,347,043.44, up from ¥373,767,202.45, indicating an increase of approximately 15.1%[31] - The company reported a total comprehensive income of ¥430,388,219.79, compared to ¥373,806,112.28 in the previous period, indicating an increase of approximately 15.1%[34] - Earnings per share (EPS) improved to ¥0.54 from ¥0.47, marking a growth of about 14.9%[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,142,610,731.93, an increase of 8.41% from the end of the previous year[7] - As of September 30, 2021, the company's total assets reached CNY 6,142,610,731.93, an increase from CNY 5,666,246,990.95 at the end of 2020[21] - The company's total liabilities decreased to CNY 1,300,441,778.73 from CNY 1,546,858,959.40, a reduction of about 16%[24] - The total liabilities decreased to ¥1,492,681,096.76 from ¥1,733,577,519.82, a reduction of about 13.9%[30] - Total assets increased to $5.69 billion, reflecting a rise of 0.4% from $5.67 billion[44] - Total liabilities amounted to $1,733,577,519.82, a decrease of $25,002,335.04 from the previous period[47] Cash Flow - The company's cash flow from operating activities decreased by 70.33% to ¥142,097,794.30 year-to-date[7] - Cash flow from operating activities was ¥2,468,152,270.44, down from ¥3,020,097,734.74, a decrease of about 18.2%[35] - The net cash flow from operating activities decreased to $142.1 million, down 70.3% from $478.9 million in the previous period[38] - Cash inflow from investment activities totaled $1.26 billion, a decrease of 46.5% compared to $2.34 billion last year[38] - The net cash flow from financing activities improved to $84.6 million, compared to a negative cash flow of $448 million in the same period last year[38] - The total cash and cash equivalents at the end of the period reached $1.39 billion, an increase of 143.4% from $569.8 million at the end of the previous period[38] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,145, with the largest shareholder holding 19.75%[13] - Total equity attributable to shareholders increased to ¥4,630,980,193.06 from ¥3,917,602,965.69, reflecting a growth of approximately 18.2%[30] - Total equity attributable to shareholders reached $3,917,602,965.69, remaining unchanged from the previous period[47] Research and Development - The company has increased its R&D investment to accelerate innovation projects, impacting cash flow[7] - Research and development expenses rose to ¥224,227,329.96 from ¥183,190,418.65, an increase of approximately 22.4%[31] Compliance and Governance - The company has established a three-party supervision agreement for the management of raised funds, ensuring compliance with regulations[20] - The company is actively implementing its fundraising projects as planned, indicating a commitment to growth and expansion[20] - The company has not audited its third-quarter report[48] - The company has implemented new lease standards since 2021, with no retrospective adjustments to prior comparative data[48] Other Financial Metrics - The company's cash and cash equivalents amounted to CNY 1,408,601,265.18, up from CNY 915,349,298.13 in December 2020, reflecting a growth of approximately 53.8%[21] - Accounts receivable increased by 35% to ¥451,898,344.25, attributed to longer collection periods due to the pandemic[9] - Inventory levels rose to CNY 572,134,799.41, compared to CNY 500,755,680.70, indicating an increase of approximately 14.2%[21] - The company reported a significant increase in non-current assets, totaling CNY 2,990,323,277.24, up from CNY 2,541,232,696.18[24] - The company reported a capital reserve of $1,897,451,568.86, unchanged from the previous period[47] - The retained earnings stood at $1,554,590,422.71, remaining stable[47] - Minority interests were recorded at $15,066,505.44, unchanged from the previous period[47]